Sylvia Lee
Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sylvia Lee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:19 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02408016 · Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or MesotheliomaFred Hutchinson Cancer Center · terminated · Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma · principal investigator
- Ph1NCT01339663 · Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic MelanomaFred Hutchinson Cancer Center · completed · Recurrent Melanoma, Stage IV Melanoma · principal investigator
- Ph1/Ph2NCT00945269 · Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV MelanomaFred Hutchinson Cancer Center · terminated · Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 9 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026Named on NCT02408016
- Career Development in Pediatric and Medical OncologyK12CA076930 · NCI · FRED HUTCHINSON CANCER CENTER · PI NANCY ELLEN DAVIDSON, SOHEIL MESHINCHI · fiscal years 2019 to 2025Named on NCT01339663, NCT00945269
- R21CA137647RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00945269
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:19 UTC. The ranking covers the 200 most relevant of 5455 PubMed records, and a shared surname and initials can bring in a namesake. All 5455 on PubMed
- 320 citationsRCR 34.5
- Colchicine in Acute Myocardial Infarction.N Engl J Med · 2025292 citationsRCR 76.5
- Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion.N Engl J Med · 2025222 citationsRCR 85.6
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps.N Engl J Med · 2025175 citationsRCR 63.3
- 169 citationsRCR 16.1
- 145 citationsRCR 14.7
- Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.N Engl J Med · 2024139 citationsRCR 18.4
- Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.N Engl J Med · 2025135 citationsRCR 26.4
- 125 citationsRCR 16.8
- 114 citationsRCR 23.0